Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

TNF-α inhibitors on par with novel biologics for resolution of dactylitis, enthesitis

12 Jan 2020

Tumour necrosis factor-α (TNF-α) inhibitors infliximab, golimumab and adalimumab are as effective as novel biologic agents ustekinumab, secukinumab and ixekizumab in the treatment of dactylitis and enthesitis, results of a systematic review and meta-analysis have shown.

The investigators performed a systematic literature search and a pooled meta-analysis of randomized controlled trials (RCTs) with TNF-α inhibitors, anti–interleukin (IL)-12/23 (ustekinumab) and anti–IL-17 (secukinumab, ixekizumab) using the random-effects model. They also assessed bias using the Cochrane risk-of-bias tool.

Eighteen RCTs including 6,981 patients were eligible for the pooled analysis. Both TNF-α inhibitors and novel biologic agents effectively resolved dactylitis at week 24 (pooled risk ratio [RR] vs placebo, 2.57, 95 percent confidence interval [CI], 1.36–4.84 and RR, 1.88, 95 percent CI, 1.33–2.65, respectively). TNF-α inhibitors (RR, 1.93, 95 percent CI, 1.33–2.79) and novel biologics (RR, 1.95, 95 percent CI, 1.60–2.38) were also effective in the resolution of enthesitis at week 24.

Both biologic categories showed overlapping ranges of American College of Rheumatology 20 responses (TNF-α inhibitors: RR, 2.23, 95 percent CI, 1.60–3.11; pooled IL-12/23 and -17: RR, 2.30, 95 percent CI, 1.94–2.72) and similar quality of life improvement scores, with mean Health Assessment Questionnaire–Disability Index score changes of –0.29 (95 percent CI, –0.39 to –0.19) and –0.26 (95 percent CI, –0.31 to –0.22), respectively.

“Biologic agents with different mechanisms of action showed efficacy in RCTs in the treatment of psoriatic arthritis,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.